Linked Data API

Show Search Form

Search Results

1584867
registered interest false more like this
date less than 2023-02-07more like thismore than 2023-02-07
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Speech and Language Therapy: Children more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of Auditory Verbal Therapy for deaf children. more like this
tabling member constituency Lewisham, Deptford more like this
tabling member printed
Vicky Foxcroft more like this
uin 141474 remove filter
answer
answer
is ministerial correction false more like this
date of answer less than 2023-02-14more like thismore than 2023-02-14
answer text <p>The Department has not made an assessment of the effectiveness of Auditory Verbal Therapy (AVT) for deaf children or the adequacy of the accessibility of AVT for deaf children on the National Health Service.</p><p>Commissioning of hearing services takes place at a local level based on the needs of the local population. The Secretary of State has, therefore, no plans to hold discussions with Auditory Verbal UK on NHS funding for early intervention programmes for deaf children.</p><p>In 2019, NHS England, with input from the National Deaf Children’s Society, produced a guide for commissioners and health and local authority providers who support children and young people with hearing loss, this can be found at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/11/what-works-chswg-guide.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/11/what-works-chswg-guide.pdf</a></p><p>The guide provides practical advice to organisations, commissioners and providers on how they can ensure children with hearing loss receive the support they need, so that they can lead successful, fulfilling and independent lives.</p>
answering member constituency Harborough more like this
answering member printed Neil O'Brien more like this
grouped question UIN
141475 more like this
141476 more like this
question first answered
less than 2023-02-14T13:13:59.987Zmore like thismore than 2023-02-14T13:13:59.987Z
answering member
4679
label Biography information for Neil O'Brien more like this
tabling member
4491
label Biography information for Vicky Foxcroft more like this
1279278
registered interest false more like this
date less than 2021-01-21more like thismore than 2021-01-21
answering body
Department for Business, Energy and Industrial Strategy more like this
answering dept id 201 more like this
answering dept short name Business, Energy and Industrial Strategy more like this
answering dept sort name Business, Energy and Industrial Strategy more like this
hansard heading Coronavirus: Vaccination more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answers of 19 January 2021 to Questions 137942 and 137941, if he will provide a breakdown of the £300 million invested in securing and scaling up UK manufacturing capacity by (a) type of capacity, (b) geographical location and (c) the date that investment was delivered. more like this
tabling member constituency Cardiff South and Penarth more like this
tabling member printed
Stephen Doughty more like this
uin 141474 remove filter
answer
answer
is ministerial correction false more like this
date of answer less than 2021-01-26more like thismore than 2021-01-26
answer text <p>The Government invested over £300 million in 2020 to secure and scale-up the UK’s manufacturing capabilities to respond to this pandemic, including:</p><p>- £127 million towards the Cell and Gene Therapy Catapult Braintree in Essex;</p><p>- £93 million to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation Centre in Oxfordshire;</p><p>- £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;</p><p>- £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire; and</p><p>- £65.5 million for the manufacture of the University of Oxford / AstraZeneca vaccine.</p><p> </p><p>In addition to the above, we have also funded the fill and finish of vaccines through a contract with Wockhardt in Wrexham, North Wales, as well as the expansion of the Valneva factory in Livingston, Scotland. However, we are not able to give further details on these two developments owing to commercial confidentiality.</p>
answering member constituency Stratford-on-Avon more like this
answering member printed Nadhim Zahawi more like this
question first answered
less than 2021-01-26T16:15:42.617Zmore like thismore than 2021-01-26T16:15:42.617Z
answering member
4113
label Biography information for Nadhim Zahawi more like this
tabling member
4264
label Biography information for Stephen Doughty more like this